Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer

Fig. 3

(Reproduced with permission from reference [161]. Copyright 2019, American Chemical Society)

Integration of siRNA and Pro-Pt into uPA peptide-targeted multifunctional shell-core NPs for the synergistic treatment of TNBC. A The tumour-targeted CaP shell-core NPs were prepared using the biomineralization method, where the organic DSPE-PEG-uPA core encapsulates the chemotherapeutic agent Pro-Pt (Pt′) followed by negatively charged siRNA adsorbing in the inorganic porous CaP shell. B The intracellular mechanism of uPA-SP@CaP NPs in TNBC cells. (i) uPA-mediated active tumour targeting increased the intracellular drug concentration. (ii) CaP-mediated lysosomal membrane rupture resulted in lysosomal escape, along with (iii) the release of the BRCA1 siRNA to inhibit the DNA repair pathway. (iv) SiRNA and reduction of Pro-Pt to Pt synergistically induced irreversible DNA damage in TNBC cells. siRNA small interfering RNA, TNBC triple-negative breast cancer

Back to article page